|1.||Steenland, Kyle: 9 articles (12/2014 - 11/2012)|
|2.||Winquist, Andrea: 7 articles (12/2014 - 08/2013)|
|3.||Shankar, Anoop: 4 articles (03/2014 - 01/2011)|
|4.||Xiao, Jie: 4 articles (03/2014 - 01/2011)|
|5.||Kennedy, Gerald L: 4 articles (08/2012 - 03/2006)|
|6.||Dai, Jiayin: 3 articles (09/2015 - 04/2008)|
|7.||Chang, Shu-Ching: 3 articles (08/2015 - 10/2010)|
|8.||Olsen, Geary W: 3 articles (07/2014 - 11/2009)|
|9.||Ducatman, Alan: 3 articles (03/2014 - 01/2011)|
|10.||Webster, Thomas F: 3 articles (03/2013 - 02/2010)|
|1.||Experimental Liver Neoplasms
06/23/1994 - "In this study, Morris hepatoma 7800C1 cells (from rat) were exposed to 500 microM perfluorooctanoic acid (PFOA) in the culture medium for 7 days. "
06/23/1994 - "Effects of perfluorooctanoic acid--a potent peroxisome proliferator in rat--on Morris hepatoma 7800C1 cells, a rat cell line."
10/05/1995 - "However, treatment of Morris hepatoma cells with the man-made peroxisome proliferator, perfluorooctanoic acid, together with all-trans-retinoic acid did not result in any synergistic effect on this same enzyme activity. "
10/05/1995 - "In summary, this study (1) corroborates findings from transfection experiments indicating that the heterodimer PPAR-RXR alpha activates transcription of the acyl-CoA oxidase gene using the Morris hepatoma cell line; (2) shows that arachidonic acid induces the activity of lauroyl-CoA oxidase; (3) suggests that transcription of the catalase gene is not regulated by a PPAR-RXR alpha heterodimer in this system; and (4) demonstrates that peroxisome proliferation in Morris hepatoma cells by perfluorooctanoic acid is not as dependent on the level of retinoic acid as is the same process caused by arachidonic acid."
|2.||Heart Diseases (Heart Disease)
10/01/2009 - "Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate."
10/01/2009 - "Based on previous findings of increased serum lipid levels associated with exposure to APFO, we evaluated ischaemic heart disease (IHD) mortality in a cohort of occupationally exposed workers. "
12/01/2014 - "Several previous studies, mostly cross-sectional, have found associations between perfluorooctanoic acid (PFOA) and high cholesterol levels, but studies of hypertension and heart disease have had inconsistent findings. "
03/01/2013 - "Perfluorooctanoic acid (PFOA) has been linked to cancer in occupational mortality studies and animal toxicologic research. "
07/01/2014 - "No association was observed between APFO exposure and kidney, prostate or breast cancers. "
07/01/2014 - "Similarly, there was little evidence that the incident cancers were associated with APFO exposure. "
07/01/2014 - "The HR for dying from the cancer and non-cancer outcomes of interest did not show an association with APFO exposure. "
07/01/2014 - "We linked a combined cohort (n=9027) of employees from APFO and non-APFO production facilities in Minnesota to the National Death Index and to cancer registries of Minnesota and Wisconsin. "
|4.||Body Weight (Weight, Body)
05/01/2009 - "The T-cell-dependent antibody response is suppressed in mice exposed to 3.75, 7.5, 15, and 30 mg PFOA (perfluorooctanoic acid)/kg body weight (bw). "
08/15/2006 - "In Phase II, APFO doses of either 10 or 30mg/kg body weight were given to groups of 23-, 30-, and 32-day-old male and female rats, and plasma was collected at 2 and 24h after the dose (separate groups), and urine was collected for 24h. "
03/15/2006 - "Mean body weights were about 20% lower in rats and mice dosed with 30 mg/kg of linear/branched or linear APFO compared to controls, and 3-5% lower in animals dosed with 30 mg/kg of branched APFO. "
12/01/1987 - "Dietary levels of 3 ppm or greater ammonium perfluorooctanoate for either 14 or 21 days produced a significant elevation in liver weight both on an absolute and on an organ/body weight ratio basis. "
08/01/2007 - "Fate of perfluorooctanoic acid (PFOA) after an intravenous injection to male rats at the dose of 0.041 mg/kg body weight was compared with that at the dose of 16.56 mg/kg body weight. "
08/01/1987 - "Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation."
09/01/2015 - "Although perfluorooctanoic acid (PFOA) is associated with hepatomegaly through peroxisome proliferator-activated receptor α (PPARα) activation, liver fat accumulation and changes in gene expression related to fatty acid metabolism could still be found in PPARα-null mice exposed to PFOA. "
10/01/2010 - "These data clearly demonstrate an early hepatocellular proliferative response to APFO treatment and suggest that the hepatomegaly and tumours observed after chronic dietary exposure of S-D rats to APFO likely are due to a proliferative response to combined activation of PPARα and CAR/PXR. "
05/01/1996 - "Perfluorooctanoic acid (PFOA) produces marked hepatic effects, including hepatomegaly, focal hepatocyte necrosis, hypolipidemia, and alteration of hepatic lipid metabolism in a number of animal species. "
10/01/2010 - "In mice, APFO-induced hepatomegaly is associated with increased activation of the xenosensor nuclear receptors, PPARα and CAR/PXR. "
|1.||perfluorooctane sulfonic acid (perfluorooctane sulfonate)
|3.||Peroxisome Proliferator-Activated Receptors (PPAR)
|7.||Arachidonic Acid (Vitamin F)
|8.||Tretinoin (Retinoic Acid)
|9.||Polychlorinated Biphenyls (PCBs)
|1.||Septal Occluder Device